Executive record

Bobak Azamian

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:bobak-azamianVersion: public-0As of: 2026-09-30

Not yet claimed5 published Claims1 sources

Key Claims

Biography

Bobak Azamian, M.D., Ph.D. serves as President, Chief Executive Officer, and Board Chairman of Tarsus Pharmaceuticals. No additional biographical detail was provided in this filing section.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2026 to end not publishedExecutive title: President, Chief Executive Officer, and Board Chairman · Organization not publishedTARS DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. TARS DEF 14A executive officers

    sec filing · Source published: Apr 28, 2026 · Retrieved: May 5, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 5, 2026
    • Executive company: Executive at Tarsus Pharmaceuticals, Inc. · Claim reviewed: May 5, 2026
    • Executive title: Executive title: President, Chief Executive Officer, and Board Chairman · Claim reviewed: May 5, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 5, 2026